Related Experiment Videos
Abstract:
Tyrosine kinase inhibitors may initially control gastrointestinal stromal tumors, but most patients eventually experience disease progression due to activation loop mutations, which are resistant to approved drugs. However, phase I trials suggest that the cancer is sensitive to two new agents: BLU-285 and DCC-2618. In addition, liquid biopsies, which were used to follow patients during the trials, may be valuable tools in tracking disease progression and assessing tumor heterogeneity.
Insights
New agents BLU-285 and DCC-2618 show promise for treating gastrointestinal stromal tumors (GIST) that resist approved drugs. Liquid biopsies may help track GIST progression and tumor diversity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Gastrointestinal stromal tumors (GIST) often develop resistance to tyrosine kinase inhibitors due to activation loop mutations.
- Approved therapies may initially control GIST but frequently fail as the cancer progresses.